The commercial complementary PD-L1 diagnostic test for nivolumab (Dako 28–8 pharmDx) and companion test for pembrolizumab (Dako 22C3 pharmDx) are now FDA approved for use in NSCLC, while the complementary test for atezolizumab (Ventana SP142) is approved for urothelial carcinoma. Here, CD274 is linked to non-small cell lung carcinoma.